e 6080 has been researched along with calcimycin in 1 studies
| Studies (e 6080) | Trials (e 6080) | Recent Studies (post-2010) (e 6080) | Studies (calcimycin) | Trials (calcimycin) | Recent Studies (post-2010) (calcimycin) |
|---|---|---|---|---|---|
| 10 | 0 | 0 | 11,946 | 40 | 444 |
| Protein | Taxonomy | e 6080 (IC50) | calcimycin (IC50) |
|---|---|---|---|
| XBP1 | Homo sapiens (human) | 1.41 | |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akutsu, I; Fukuda, T; Makino, S; Motojima, S; Numao, T; Toda, M | 1 |
1 other study(ies) available for e 6080 and calcimycin
| Article | Year |
|---|---|
Inhibition of leukotriene C4 and B4 release by human eosinophils with the new 5-lipoxygenase inhibitor 6-hydroxy-2(4-sulfamoylbenzylamino)-4,5,7-trimethylbenzothiazo le hydrochloride.
Topics: Asthma; Calcimycin; Dose-Response Relationship, Drug; Eosinophils; Humans; In Vitro Techniques; Ionophores; Leukotriene B4; Leukotriene C4; Lipoxygenase Inhibitors; Platelet Activating Factor; Thiazoles | 1995 |